Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sagimet Biosciences Inc.
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 20, 2026
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 20, 2026
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 19, 2026
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
April 27, 2026
Sagimet Biosciences Provides Strategic and Corporate Updates
April 27, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
1
2
Next Page
→